James E. Fickenscher
2015 - Antares Pharma
In 2015, James E. Fickenscher earned a total compensation of $1.1M as Chief Financial Officer at Antares Pharma, a 402% increase compared to previous year.
Compensation breakdown
| Bonus | $1,000 |
|---|---|
| Non-Equity Incentive Plan | $144,480 |
| Option Awards | $227,522 |
| Salary | $350,000 |
| Stock Awards | $406,192 |
| Other | $12,959 |
| Total | $1,142,153 |
Fickenscher received $406.2K in stock awards, accounting for 36% of the total pay in 2015.
Fickenscher also received $1K in bonus, $144.5K in non-equity incentive plan, $227.5K in option awards, $350K in salary and $13K in other compensation.
Rankings
In 2015, James E. Fickenscher's compensation ranked 7,302nd out of 13,638 executives tracked by ExecPay. In other words, Fickenscher earned more than 46.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,302 out of 13,638 | 47th |
Division Manufacturing | 2,746 out of 5,187 | 47th |
Major group Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks | 352 out of 754 | 53rd |
Industry group Surgical, Medical, And Dental Instruments And Supplies | 194 out of 460 | 58th |
Industry Surgical and Medical Instruments and Apparatus | 104 out of 287 | 64th |
Source: SEC filing on April 22, 2016.
Fickenscher's colleagues
We found four more compensation records of executives who worked with James E. Fickenscher at Antares Pharma in 2015.
News
Zynerba Pharmaceuticals CEO Armando Anido's 2022 pay slips 15% to $1.9M
April 21, 2023
Zynerba Pharmaceuticals CEO Armando Anido's 2021 pay jumps 49% to $2.2M
April 25, 2022
Zynerba Pharmaceuticals CEO Armando Anido's 2020 pay rises 8% to $1.5M
April 21, 2021
Zynerba Pharmaceuticals CEO Armando Anido's 2019 pay falls 32% to $1.4M
April 23, 2020
Zynerba Pharmaceuticals CEO Armando Anido's 2018 pay slips 18% to $2M
April 25, 2019